Is Gujarat Kidney and Super Speciality a Good Buy After Its Q1 FY27 Results?
- September 11, 2026
- Posted by: Harsh Piplani
- Category: Market
Gujarat Kidney and Super Speciality share price around Rs 173. 4.4% below 52-week high of Rs 180. Q1 FY27 revenue Rs 35 crore, up 129.1% YoY. PAT Rs 5.32 crore, down 1.5%. PE 82x.
Quick Answer
Gujarat Kidney and Super Speciality’s Q1 FY27 results were mixed, with revenue at Rs 35 crore but PAT falling 1% to Rs 5.32 crore. The Gujarat Kidney and Super Speciality share price near Rs 173 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Gujarat Kidney and Super Speciality is a good buy right now.
The Gujarat Kidney and Super Speciality share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Gujarat Kidney and Super Speciality is a recently listed hospital chain specializing in renal, vascular and other super-speciality surgeries, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 35 crore, up 129.1% year on year, while profit after tax came in at Rs 5.32 crore, down 1.5% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Gujarat Kidney and Super Speciality share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Gujarat Kidney and Super Speciality share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Gujarat Kidney and Super Speciality Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 35 crore | Rs 15 crore | 129.1% |
| EBITDA | Rs 9.07 crore | Rs 8.63 crore | 5.1% |
| Operating Margin | 26.4% | 56.5% | NA |
| Profit Before Tax | Rs 6.96 crore | Rs 7.49 crore | -7.1% |
| Net Profit / (Loss) | Rs 5.32 crore | Rs 5.40 crore | -1.5% |
Gujarat Kidney and Super Speciality Q1 FY27 Performance Analysis
Check Gujarat Kidney and Super Speciality Fundamentals on Univest Screener
Revenue growth of 129.1% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the hospital and healthcare services, specializing in renal and super-speciality surgery sector.
Profitability is where the quarter disappointed. PAT fell 1% year on year to Rs 5.32 crore even as revenue grew, which points to margin or cost pressure that management will need to address. This gap between top-line and bottom-line performance is the key thing weighing on the Gujarat Kidney and Super Speciality share price this quarter.
On a sequential basis, revenue moved up 11.8% sequentially from Rs 31 crore in the March 2026 quarter and net profit moved up 10.1% sequentially from Rs 4.83 crore in the prior quarter, giving a fuller picture of the trend behind the Gujarat Kidney and Super Speciality share price than the year on year comparison alone.
Key Business Factors in Q1 FY27
Revenue Trend
Gujarat Kidney and Super Speciality’s revenue grew 129.1% year on year this quarter, taking the quarterly base to Rs 35 crore in a hospital and healthcare services, specializing in renal and super-speciality surgery business that remains sensitive to demand and pricing cycles that ultimately feed through to the Gujarat Kidney and Super Speciality share price.
Margin Movement
EBITDA rose 5.1% to Rs 9.07 crore, and operating margin moved to 26.4% from 56.5% a year earlier, a sign that cost control or pricing held up during the quarter.
Balance Sheet Position
Gujarat Kidney and Super Speciality carries a low debt-to-equity ratio of 0.12, giving it a conservative balance sheet heading into the rest of FY27.
Valuation Context
The stock trades at a PE of 81.8x against an industry average of 68.5x, a premium that this quarter’s results will need to justify going forward.
Dividend Details
No interim dividend was declared alongside Gujarat Kidney and Super Speciality’s Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Gujarat Kidney and Super Speciality share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Gujarat Kidney and Super Speciality Share Price Outlook for FY27
The key question for the rest of FY27 is whether Gujarat Kidney and Super Speciality can arrest the margin pressure seen this quarter. Revenue growth alone will not be enough to support the Gujarat Kidney and Super Speciality share price if profitability keeps slipping, so investors should watch the next couple of quarters for signs of a turnaround in the bottom line.
A stabilising or improving margin trend in the next result would be the clearest signal that this quarter’s profit decline was a temporary setback rather than the start of a longer slide for the Gujarat Kidney and Super Speciality share price.
Gujarat Kidney and Super Speciality Stock Performance
Download the Univest iOS App or Univest Android App to track Gujarat Kidney and Super Speciality’s live share price and get daily stock updates.
The Gujarat Kidney and Super Speciality share price was trading around Rs 173 as results season played out in late August 2026, roughly 4.4% below its 52-week high of Rs 180 and well above its 52-week low of Rs 98.
The Gujarat Kidney and Super Speciality share price has likely already absorbed some of this quarter’s disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 6.14% and a book value of around Rs 32 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Valuation Risk
At 81.8x earnings against an industry average of 68.5x, the stock leaves little room for disappointment if growth slows.
Profitability Risk
The quarter’s profit trend is the clearest risk here. Until Gujarat Kidney and Super Speciality shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.
Sector and Demand Risk
As a hospital and healthcare services, specializing in renal and super-speciality surgery business, Gujarat Kidney and Super Speciality’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Gujarat Kidney and Super Speciality share price well before the next result.
Conclusion
Gujarat Kidney and Super Speciality’s Q1 FY27 results show a business still growing its top line but losing ground on profitability, with PAT down 1% to Rs 5.32 crore even as revenue rose. The Gujarat Kidney and Super Speciality share price reflects a stock in wait-and-watch mode, and it is not an obvious buy purely on this quarter’s numbers until the margin trend turns around.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Gujarat Kidney and Super Speciality Q1 FY27 Results
What were Gujarat Kidney and Super Speciality’s Q1 FY27 results?
Ans. Gujarat Kidney and Super Speciality reported Q1 FY27 revenue of Rs 35 crore, up 129.1% year on year, and PAT of Rs 5.32 crore, down 1.5% year on year.
Is Gujarat Kidney and Super Speciality a good buy after its Q1 FY27 results?
Ans. Gujarat Kidney and Super Speciality’s profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.
What is the Gujarat Kidney and Super Speciality share price today?
Ans. The Gujarat Kidney and Super Speciality share price was trading around Rs 173 in late August 2026, about 4.4% below its 52-week high of Rs 180 and well above its 52-week low of Rs 98.
What is Gujarat Kidney and Super Speciality’s revenue and profit for Q1 FY27?
Ans. Gujarat Kidney and Super Speciality reported revenue of Rs 35 crore and a net profit of Rs 5.32 crore for the quarter ended June 30, 2026.
Did Gujarat Kidney and Super Speciality declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Gujarat Kidney and Super Speciality’s Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Gujarat Kidney and Super Speciality’s PE ratio and is it expensive?
Ans. The Gujarat Kidney and Super Speciality share price trades at a trailing PE of 81.8x, against an industry average of 68.5x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Gujarat Kidney and Super Speciality investors right now?
Ans. At 81.8x earnings against an industry average of 68.5x, the stock leaves little room for disappointment if growth slows. As a hospital and healthcare services, specializing in renal and super-speciality surgery business, Gujarat Kidney and Super Speciality’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Gujarat Kidney and Super Speciality share price well before the next result.
What is Gujarat Kidney and Super Speciality’s promoter shareholding?
Ans. Promoter shareholding data for Gujarat Kidney and Super Speciality was not fully available for this quarter and should be checked on the company’s official filings.
